Letters
Impact of DOTS and DOTS-plus on multidrug resistant TB: DOTS-plus strengthens, not weakens, DOTS programmes
BMJ 2003; 327 doi: https://doi.org/10.1136/bmj.327.7407.164 (Published 17 July 2003) Cite this as: BMJ 2003;327:164- Edward A Nardell (enardell@pih.org), associate professor
- Department of Social Medicine, Harvard Medical School, 641 Huntington Avenue, Boston, MA 02115, USA
EDITOR—In their decision analysis Sterling et al hypothesise but offer no evidence that the efficacy of DOTS (directly observed treatment, short course) has ever been diminished by DOTS-plus.1 On the contrary, under the current rigorous procedure for obtaining second line drugs at drastically reduced prices, the Green Light Committee of the World Health Organization assures that only programmes with demonstrably strong DOTS and DOTS-plus components are approved, …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.